Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits of hepatic arterial infusion chemotherapy (HAIC) for advanced HCC with main po...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2021, 15(2), , pp.284-294
Main Authors: Ahn, Young Eun, Suh, Sang Jun, Yim, Hyung Joon, Seo, Yeon Seok, Yoon, Eileen L, Kim, Tae Hyung, Lee, Young Sun, Yim, Sun Young, Kim, Hae Rim, Kang, Seong Hee, Jung, Young Kul, Kim, Ji Hoon, Yeon, Jong Eun, Um, Soon Ho, Byun, Kwan Soo
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols
carcinoma
Carcinoma, Hepatocellular - complications
Carcinoma, Hepatocellular - drug therapy
chemotherapy
hepatic artery
hepatocellular
Humans
Liver Neoplasms - complications
Liver Neoplasms - drug therapy
Original
Portal Vein
portal vein thrombosis
sorafenib
Sorafenib - therapeutic use
Thrombosis
Treatment Outcome
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits of hepatic arterial infusion chemotherapy (HAIC) for advanced HCC with main portal vein tumor thrombosis (PVTT). This study aimed to compare the efficacy of sorafenib-based therapy with that of HAIC-based therapy for advanced HCC with main PVTT. Advanced HCC patients with main PVTT treated with sorafenib or HAIC between 2008 and 2016 at Korea University Medical Center were included. We evaluated overall survival (OS), time-to-progression (TTP), and the disease control rate (DCR). Seventy-three patients were treated with sorafenib (n=35) or HAIC (n=38). Baseline characteristics were not significantly different between groups, except the presence of solid organ metastasis (46% vs 5.3%, p
ISSN:1976-2283
2005-1212
DOI:10.5009/gnl19367